The 10Q is out (2/20/2007).

Not a surprise to me is that BioAgra has not made any money (yet) and VytaCorp keeps sending them money to keep on going.

What did surprise me is the revenue from ExypnoTech GmbH.

<CAPTION>
              Three Months   Three Months    Six Months     Six Months
                 Ended          Ended          Ended          Ended
              December 31,   December 31,   December 31,   December 31,
                  2006           2005           2006           2005
             --------------  -------------  -------------  -------------
<S>          <C>             <C>            <C>            <C>
Revenues(1)  $   1,271,198        645,460      1,839,740      1,045,196
Expenses(2)     (1,182,660)      (707,287)    (1,674,991)    (1,141,600)
             --------------  -------------  -------------  -------------
Net income
  (loss)     $      88,538        (61,827)       164,749        (96,404)
             ==============  =============  =============  =============

The revenue from last quarter of $1.27 million is strong growth from the $1/2 million of the previous quarter $568K.

Also, buried deep in the filing, is something that I hope to see come to fruition and vindicates (in addition to ExypnoTech's growth and success). I cut/paste:

"... in January 2007 the Company signed a six-month Technology Agreement to permit a prospective licensee the opportunity to conduct a market survey relating to its NCOS(TM) technology. We believe that if the market survey is favorable the Technology Agreement may mature into a royalty paying commercial license the terms and conditions of which are under negotiation between the Company and the perspective licensee."